Table 1.
Demographic, clinical, and molecular features of the patients enrolled in the study.
| Tot (n = 62) * | |
|---|---|
| Demographics | |
| Male sex | 35 (56.5%) |
| Age at inclusion, median (IQR) | 67 (61–74) |
| Histology | |
| Adenocarcinoma | 55 (88.7%) |
| Mucinous adenocarcinoma | 7 (11.3%) |
| Grading | |
| G2 | 26 (41.9%) |
| G3 | 11 (17.7%) |
| G4 | 1 (1.6%) |
| Missing | 24 (38.7%) |
| Site of primary lesion | |
| Colon | 46 (74.2%) |
| Rectal | 10 (16.1%) |
| Transverse colon | 2 (3.2%) |
| Missing | 4 (6.5%) |
| Staging | |
| IV (new diagnosis) | 21 (33.9%) |
| IV (relapse) | 14 (22.6%) |
| Missing | 27 (43.6%) |
| Number of metastases | |
| 1 | 28 (45.2%) |
| 2 | 24 (38.7%) |
| 3+ | 10 (16.1%) |
| Site of metastasis | |
| Liver | 37 (59.7%) |
| Lung | 18 (29.0%) |
| Loco-regional | 12 (19.4%) |
| Lymph nodes | 12 (19.4%) |
| Peritoneum | 12 (19.4%) |
| Pleura | 5 (8.1%) |
| Adrenal gland | 3 (4.8%) |
| Bone | 2 (3.2%) |
| Kidney | 2 (3.2%) |
| Pancreas | 1 (1.6%) |
| Endometrium | 1 (1.6%) |
| Bladder | 1 (1.6%) |
| Brain | 1 (1.6%) |
| Surgery on primary site | 48 (77.4%) |
| Chemotherapy | |
| Yes | 47 (75.8%) |
| No | 1 (1.6%) |
| Missing | 14 (22.6%) |
| Chemotherapy agents | |
| Only synthetic agents | 17 (27.4%) |
| Only targeted biologics | 5 (8.1%) |
| Combination of synthetic and biologics | 25 (40.3%) |
* n (%) or median (IQR).